Alpharma to acquire generic oral drug business of Faulding

11 July 2001

Alpharma of the USA has signed an agreement to acquire the genericoral solid-dose pharmaceutical businesses of Australia-headquarted FH Faulding from Mayne Nickless, once the latter has completed its purchase of Faulding's overall health care and pharmaceutical businesses.

Alpharma is to pay approximately $660 million in cash for the businesses, which include the operations of Purepac Pharmaceuticals and Faulding Laboratories in the USA. Revenues for these operations are around $200 million annually. Meantime, Israel's Teva Pharmaceutical Industries is to buy Faulding's injectables unit from Mayne Nickless.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight